Implications of KRAS status in first-line chemotherapy with bevacizumab in advanced colorectal cancer: A phase IV study of Hellenic Oncology Research Group (HORG). Authors: Anna Koumarianou, Nikolaos Ziras, Stylianos Kakolyris, Michael Vaslamatzis, Aristidis Polyzos, Nikolaos K. Kentepozidis, Athina Christopoulou, Spyros Xynogalos, Athanasios Athanasiadis, Ilias Athanasiadis, Athanasios Anagnostopoulos, Athanasios Karampeazis, Christos E. Emmanouilides, Ioannis Boukovinas, Paris Makrantonakis, Charalambos Kouroussis, Efthimios Prinarakis, Dora Hatzidaki, Vassilis Georgoulias; Hellenic Oncology Research Group (HORG), Athens, Greece; Hellenic Oncology Research Group (HORG), Athens, AZ, Greece.J Clin Oncol 36, 2018 (suppl; abstr e15521). http://abstracts.asco.org/214/AbstView_214_220989.html

Phase II study of cabazitaxel as second-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes. Authors: Angelos Koutras, Flora Zagouri, Georgia-Angeliki Koliou, Georgios Lazaridis, Dimitrios Tryfonopoulos, Athanasios Kotsakis, Eleni Res, Nikolaos K. Kentepozidis, Evangelia Razis, Amanda Psyrri, Georgios Koumakis, Haralabos Kalofonos, George Fountzilas, Meletios A. Dimopoulos; Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece. J Clin Oncol 36, 2018 (suppl; abstr 1089). http://abstracts.asco.org/214/AbstView_214_224945.html

ISO-CC-005: A phase I/II study of Modufolin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer. Authors: Helena Anna Taflin, Karin M E Ganlov, Tormod Kyrre Guren, Christos Papadimitrou, Nikolaos K. Kentepozidis, Johan Haux, Per Pfeiffer, Goran Ulf Carlsson; Sahlgrenska University Hospital, Gothenburg, Sweden; Isofol Medical AB, Gothenburg, Sweden; Oslo University Hospital, Oslo, Norway; University of Athens, Aretaieio Hospital, Athens, Greece; Hellenic Airforce General Hospital, Athens, Greece; Skaraborgs Hospital/Skovde, Skovde, Sweden; Odense University Hospital, Odense, Denmark. J Clin Oncol 36, 2018 (suppl 4S; abstr 838).

Three versus six months adjuvant oxaliplatin plus fluoropyrimidine chemotherapy for patients with stage III colon cancer: The Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant (IDEA) chemotherapy  project. Authors: John Souglakos, Ioannis Boukovinas, Spyros Xynogalos, Stylianos Kakolyris, Nikolaos Ziras, Michael Vaslamatzis, Alexandros Ardavanis, Athanasios Athanasiadis, Nikolaos E. M. Androulakis, Nikolaos K. Kentepozidis, Athina Christopoulou, Paris Makrantonakis, Ioannis I. Varthalitis, Charalampos Christofyllakis, Christos E. Emmanouilides, Dimitrios Mavroudis, Efthimios Prinarakis, Aggeliki Kalisperi, Dora Hatzidaki, Vassilis Georgoulias; Hellenic Oncology Research Group, Athens, Greece. J Clin Oncol 36, 2018 (suppl 4S; abstr 730)  https://meetinglibrary.asco.org/record/155659/abstract

Phase II trial of modified FOLIRI plus Panitumumab as first-line treatment in elderly patients with RAS wild-type metastatic colorectal cancer. Author(s): Athanasios Karampeazis, Lampros Vamvakas, Nikolaos K. Kentepozidis, Athanasios Kotsakis, Kostas Kalbakis, Spyros Xynogalos, Ioannis Sougklakos, Christos E. Emmanouilides, Alexandra Voutsina, Dora Hatzidaki, Vassilis Georgoulias; Hellenic Oncology Research Group (HORG), Athens, GreeceJ , Clin Oncol 35, 2017 (suppl; abstr e15053) http://abstracts.asco.org/199/AbstView_199_192537.html

The Greek participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study of 3 versus 6 months of adjuvant chemotherapy in stage III colon cancer: Patients’ characteristics and safety analysis. John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris, Nikolaos Ziras, Nikolaos E. M. Androulakis, Alexandros Ardavanis, Nikolaos K. Kentepozidis, Michael Vaslamatzis, Athanasios Athanasiadis, Athina Christopoulou, Paris Makrantonakis, Aristidis Polyzos, Dimitrios Mavroudis, Anastasia Mala, Aggeliki Kalisperi, Spyros Xynogalos, Ioannis I. Varthalitis, Charalambos Kouroussis, Efthimios Prinarakis, Vassilis Georgoulias; Hellenic Oncology Research Group (HORG), Athens, Greece, J Clin Oncol 35, 2017 (suppl 4S; abstract 740)

Salvage treatment of relapsed/refractory small cell lung cancer with pazopanib: A Hellenic Oncology Research Group’s (HORG) phase II study. Athanasios Kotsakis,   Vasilis Karavasilis, Sofia Agelaki, Nikolaos K. Kentepozidis, Stavros Peroukidis, Epaminontas Samantas, Charalampos Christofyllakis, Eleftheria- Kleio Dermitzaki, Filippos Koinis, E Hartabilas, George Fountzilas, Efthimios Prinarakis, Vassilis Georgoulias; Hellenic Oncology Research Group (HORG), Athens, Greece, J Clin Oncol 34, 2016 (suppl; abstr 8561)

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pretreated with a non-platinum-based regimen in the first-line setting: A randomized phase II study of the Hellenic Oncology Research Group (HORG). Nikolaos K. Kentepozidis, Panagiota Economopoulou, Charalampos Christophyllakis,Leonidas Chelis, Aristidis Polyzos, Nikolaos Vardakis, Filippos Koinis, Christos Nikolaou, Vassilis Georgoulias, and Athanasios Kotsakis ASCO MEETING ABSTRACTS May 18, 2015:e19044

Everolimus as second-line treatment in metastatic renal cell carcinoma (mRCC) after first-line pazopanib (The RESCUE study): A retrospective analysis by the Hellenic GU Cancer Group (HGUCG) with international collaboration. Konstantinos Koutsoukos, Marta Espinosa Montano, Loukas Kontovinis, Kimon Tzannis, Angelos Koutras, Christos Christodoulou, Vasiliki Bozionelou, Dimitra Stefanou, Marios Bakogeorgos, Nikolaos K. Kentepozidis, Alexandros Ardavanis, Haralabos Kalofonos, Ignacio Duran, Aristotelis Bamias, Konstantinos Papazisis, and Hellenic Genito-Urinary Cancer Group (HGUCG)ASCO MEETING ABSTRACTS May 18, 2015:e15601

Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. L. VamvakasS. Agelaki, N. K. Kentepozidis, A. Karampeazis, A. G. Pallis, C. Christophyllakis, A. P. Kotsakis, I. Boukovinas, D. Mavroudis, and V. Georgoulias ASCO MEETING ABSTRACTS Jun 14, 2010:7519

Bortezomib in combination with gemcitabine (GEM) and cisplatin (CDDP) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC): A Hellenic Oncology Research Group multicenter phase II study. Sofia Agelaki, Athanasios Kotsakis, Emmanouil Kontopodis, Nikolaos K. Kentepozidis, Konstantinos N. Syrigos, Nikolaos Ziras, Georgia Filippa, Lampros Vamvakas, Dimitrios Mavroudis, and Vassilis Georgoulias ASCO MEETING ABSTRACTS Jun 11, 2014:e19050

Patterns of practice in the management of advanced urothelial cancer (UC) in Greece: A retrospective analysis by the hellenic GU Cancer Group (HGUCG). Stavros Peroukidis, Maria Likka, Charalampos Andreadis, Vasiliki Bozionelou, Kimon Tzanis, Nikolaos Fragkiskos Pistamaltzian, Ioannis I. Varthalitis, Michalis Karamouzis, Georgia Milaki, Antonios Agorastos, Nikolaos Diamantis, Evangelos Lianos, Nikolaos K. Kentepozidis, Nikos Fytrakis, Iliada Bompolaki, Nikolaos E. M. Androulakis, Ilias Athanasiadis, Haralabos Kalofonos, Dimitrios Mavroudis, Aristotelis Bamias, and Hellenic GU Cancer Group ASCO MEETING ABSTRACTS Jun 11, 2014:e15514

A phase II trial of cabazitaxel in patients with metastatic NSCLC progressing after docetaxel-based treatment. Athanasios Kotsakis, Nikolaos K. Kentepozidis, Ioannis I. Varthalitis, Vasilios Karavasilis, Epaminontas Samantas, Charalampos Christophyllakis, Eleftheria- Kleio Dermitzaki, Nikolaos Ziras, Sofia Agelaki, Haralambos P. Kalofonos, Dimitrios Mavroudis, and Vassilis Georgoulias ASCO MEETING ABSTRACTS Jun 11, 2014:8102

A multicenter phase I-II trial of weekly paclitaxel and carboplatin plus bevacizumab in women with triple-negative metastatic breast cancer. Emmanouil S. Saloustros, Aristidis Polyzos, Charalampos Christophyllakis, Nikolaos K. Kentepozidis, Lampros Vamvakas, Kostas Kalbakis, Sofia Agelaki, Vassilis Georgoulias, and Dimitrios Mavroudis ASCO MEETING ABSTRACTS Jun 17, 2013:1045

A multicenter, randomized phase II study of sequential vinorelbine (V)/cisplatin (C)/bevacizumab (B) followed by docetaxel (D)/gemcitabine (G)/B versus D/C/B as a first-line therapy for advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). Athanasios Panayotis Kotsakis, Emmanouil Kontopodis, Nikolaos Vardakis, Kostas Kalbakis, Nikolaos K. Kentepozidis,Alexandros Xyrafas, Charalampos Christophyllakis, Dimitrios Mavroudis, and Vassilis Georgoulias ASCO MEETING ABSTRACTSMay 30, 2012:e18105

Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase III Hellenic Oncology Research Group trial. A. Karampeazis, L. Vamvakas, A. G. Pallis, C. Christophyllakis, N. K. Kentepozidis, V. Chandrinos, A. Polyzos, A. Athanasiadis, G. Milaki, and V. Georgoulias ASCO MEETING ABSTRACTS Jun 14, 2010:7605

CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC).  N. Ziras, A. Polyzos, N. Xenidis, A. Kalykaki, N. E. Androulakis, P. Papakotoulas, N. K. Kentepozidis,P. Makrantonakis, S. Xynogalos, and I. Sougklakos ASCO MEETING ABSTRACTS Jun 14, 2010:3542

CAPIRI (capecitabine, irinotecan) + bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) + bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial N. Ziras, A. Polyzos, S. Kakolyris, N. Xenidis, N. Kentepozidis, A. Athanasiadis, I. Stergiou, N. Androulakis, L. Vamvakas, and J. Souglakos ASCO MEETING ABSTRACTS Aug 18, 2008:15008

Phase III randomized study of oral vinorelbine (oV) and gemcitabine (G) (oVG) versus docetaxel (D) and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): A preliminary report S. Agelaki, N. Androulakis, A. Agelidou, M. Agelidou, A. Kotsakis, S. Kakolyris, A. Polyzos, N.Kentepozidis, N. Ziras, and D. Mavroudis ASCO MEETING ABSTRACTS Jun 21, 2007:7538

Correlation of gefitinib efficacy and detection of new EGFR mutation variants in pre-treated patients (pts) with advanced non- small cell lung cancer (NSCLC) A. Pallis, A. Voutsina, A. Kalikaki, A. Koutsopoulos, J. Souglakos, C. Christophylakis, N. Kentepozidis, S. Giassas, D. Mavroudis, and V. Georgoulias ASCO MEETING ABSTRACTS Jun 21, 2007:18062

Phase I study of gemcitabine (GEM) and premetrexed (ptx) in the treatment of advanced solid tumors A. Kalykaki, S. Agelaki, K. Kalbakis, A. Kotsakis, N. Kentepozidis, C. Christophyllakis, S. Giassas, L. Vamvakas, N. Vardakis, and D. Mavroudis ASCO MEETING ABSTRACTS Jun 16, 2006:12025

A phase II study of docetaxel plus irinotecan (DOCIRI) in chemo-naive patients with non small cell lung cancer (NSCLC)  P. ZiotopoulosV. Chandrinos, N. Samaras, E. Mylonaki, J. Stergiou, E. Zachariadis, X. Tsiafaki, A. Agelidou, N. Ketepozidis, and V. Georgoulias ASCO MEETING ABSTRACTS Sep 3, 2004:7267